MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.transproceed.2022.04.025

Медицинская библиотека · Transplantation proceedings · 2022

Hepatitis E Diagnosis and Management After Liver, Kidney, or Heart Transplant: A Single-Center Experience.

Carter Maximilian, Solsrud Kassandra, Yeddula Sirisha, Fitzmaurice Mary Grace, Singh Ashina, Nagai Shunji, Jafri Syed-Mohammed

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Transplant-related hepatitis E virus (HEV) infection is a rarely recognized phenomenon with significant clinical importance given its potential to result in chronic hepatitis posttransplant.

METHODS

We retrospectively evaluated HEV diagnosis and treatment after liver, kidney, and heart transplant in a single center. We identified patients diagnosed with HEV by serologic testing and evaluated their treatment regimens.

RESULTS

Fifteen transplant recipients (12 liver, 2 kidney, and 1 heart) presented with elevated liver enzymes and were positive for HEV IgM antibody. Liver enzymes normalized in 4 patients after being treated with ribavirin. One of the 4 patients had 2 recurrences with positive HEV RNA results following ribavirin treatment but recovered after 12 months of ribavirin therapy. After treatment with reduction in immunosuppression without antiviral treatment, 6 of 8 patients' liver enzymes normalized. One of these patients died of acute pancreatitis 2 months after testing positive for HEV IgM antibody.

CONCLUSIONS

The potential for complications related to active HEV infections in transplant recipients necessitates prompt diagnosis and treatment to prevent irreversible damage. Diagnosis with HEV reverse transcriptase-polymerase chain reaction should follow a positive HEV IgM antibody test. This manuscript provides evidence that ribavirin antiviral therapy and reducing immunosuppression are effective treatments for HEV infections in liver, kidney, and heart transplant recipients, which has not been sufficiently investigated in the population of the United States. Larger multicenter studies are needed to confirm the risks and benefits of using ribavirin antiviral therapy as first-line therapy of HEV posttransplant.

Для цитирования: Carter Maximilian, Solsrud Kassandra, Yeddula Sirisha, Fitzmaurice Mary Grace, Singh Ashina, Nagai Shunji, Jafri Syed-Mohammed. Hepatitis E Diagnosis and Management After Liver, Kidney, or Heart Transplant: A Single-Center Experience.. Transplantation proceedings. 2022. DOI: 10.1016/j.transproceed.2022.04.025.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.